NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2018 Update

NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2018 Update


  • Products Id :- GDME36072PD
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

NovoCure Ltd (NovoCure) is an drug company that offers development and commercialization of novel therapies for tumor treating fields. The company's pipeline products find application in cancer indications such as malignant melanoma, hepatocellular carcinoma, ovarian cancer, breast cancer and small cell lung cancer, among others. It also offers provides products for other indications such as glioblastoma and diagnosed glioblastoma, among others. Novocure owns and operates a research centre in Haifa, Israel; and operates along with its subsidiaries located in the US; Berlin, and Germany. The company has its operations in Japan and Switzerland. NovoCure is headquartered in St. Helier, the UK.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company NovoCure Ltd

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

NovoCure Ltd Company Overview 6

NovoCure Ltd Company Snapshot 6

NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview 6

NovoCure Ltd - Pipeline Analysis Overview 9

NovoCure Ltd - Key Facts 9

NovoCure Ltd - Major Products and Services 10

NovoCure Ltd Pipeline Products by Development Stage 11

NovoCure Ltd Ongoing Clinical Trials by Trial Status 13

NovoCure Ltd Pipeline Products Overview 15

Optune - Brain Metastasis 15

Optune - Brain Metastasis Product Overview 15

Optune - Brain Metastasis Clinical Trial 16

Optune - Breast Cancer 18

Optune - Breast Cancer Product Overview 18

Optune - Cervical Cancer 19

Optune - Cervical Cancer Product Overview 19

Optune - Colorectal Carcinoma 20

Optune - Colorectal Carcinoma Product Overview 20

Optune - Gastric Adenocarcinoma 21

Optune - Gastric Adenocarcinoma Product Overview 21

Optune - Hepatocellular Carcinoma 22

Optune - Hepatocellular Carcinoma Product Overview 22

Optune - Malignant Melanoma 23

Optune - Malignant Melanoma Product Overview 23

Optune - Mesothelioma 24

Optune - Mesothelioma Product Overview 24

Optune - Mesothelioma Clinical Trial 25

Optune - Non - Small Cell Lung Cancer 26

Optune - Non - Small Cell Lung Cancer Product Overview 26

Optune - Ovarian Cancer 27

Optune - Ovarian Cancer Product Overview 27

Optune - Ovarian Cancer Clinical Trial 28

Optune - Pancreatic Cancer 29

Optune - Pancreatic Cancer Product Overview 29

Optune - Pancreatic Cancer Clinical Trial 30

Optune - Pediatric Glioma 31

Optune - Pediatric Glioma Product Overview 31

Optune - Pediatric Glioma Clinical Trial 32

Optune - Prostate Cancer 33

Optune - Prostate Cancer Product Overview 33

Optune - Renal Adenocarcinoma 34

Optune - Renal Adenocarcinoma Product Overview 34

Optune - Squamous Non-Small Cell Lung Cancer 35

Optune - Squamous Non-Small Cell Lung Cancer Product Overview 35

Optune - Urinary Transitional Cell Carcinoma 36

Optune - Urinary Transitional Cell Carcinoma Product Overview 36

Optune Plus Bevacizumab - Recurrent Glioblastoma 37

Optune Plus Bevacizumab - Recurrent Glioblastoma Product Overview 37

Optune With Marizomib And Temozolomide - Glioblastoma 38

Optune With Marizomib And Temozolomide - Glioblastoma Product Overview 38

NovoCure Ltd - Key Competitors 39

NovoCure Ltd - Key Employees 40

NovoCure Ltd - Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

NovoCure Ltd, Recent Developments 42

Jul 02, 2018: Novocure Names Pritesh Shah As Chief Commercial Officer 42

Jun 04, 2018: Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018 42

May 31, 2018: Novocure Announces Changes to Its Board of Directors 42

May 28, 2018: Update on Mithra and Mayne Pharma's Vaginal Contraceptive Ring Opportunity 43

Apr 26, 2018: Novocure Reports First Quarter 2018 Financial Results and Provides Company Update 44

Apr 17, 2018: Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma 45

Apr 13, 2018: Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting 46

Mar 20, 2018: NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma 46

Mar 15, 2018: Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018 47

Feb 22, 2018: Novocure Announces Fourth Quarter and Full Year 2017 Financial Results 49

Appendix 52

Methodology 52

About GlobalData 55

Contact Us 55

Disclaimer 55

List of Figures

NovoCure Ltd Pipeline Products by Equipment Type 7

NovoCure Ltd Pipeline Products by Development Stage 11

NovoCure Ltd Ongoing Clinical Trials by Trial Status 13

List of Tables

NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview 6

NovoCure Ltd Pipeline Products by Equipment Type 7

NovoCure Ltd Pipeline Products by Indication 8

NovoCure Ltd Ongoing Clinical Trials by Trial Status 8

NovoCure Ltd, Key Facts 9

NovoCure Ltd, Major Products and Services 10

NovoCure Ltd Number of Pipeline Products by Development Stage 11

NovoCure Ltd Pipeline Products Summary by Development Stage 12

NovoCure Ltd Ongoing Clinical Trials by Trial Status 13

NovoCure Ltd Ongoing Clinical Trials Summary 14

Optune - Brain Metastasis - Product Status 15

Optune - Brain Metastasis - Product Description 15

Optune - Brain Metastasis - A Phase II Randomized Study of TTField Therapy (150 kHz) Versus Supportive Care in Non-small Cell Lung Cancer Patients with 1-5 Brain Metastases Following Optimal Standard Local Treatment 16

Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma 16

Optune - Brain Metastasis - Pivotal, Open-label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) (150kHz) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC) 17

Optune - Breast Cancer - Product Status 18

Optune - Breast Cancer - Product Description 18

Optune - Cervical Cancer - Product Status 19

Optune - Cervical Cancer - Product Description 19

Optune - Colorectal Carcinoma - Product Status 20

Optune - Colorectal Carcinoma - Product Description 20

Optune - Gastric Adenocarcinoma - Product Status 21

Optune - Gastric Adenocarcinoma - Product Description 21

Optune - Hepatocellular Carcinoma - Product Status 22

Optune - Hepatocellular Carcinoma - Product Description 22

Optune - Malignant Melanoma - Product Status 23

Optune - Malignant Melanoma - Product Description 23

Optune - Mesothelioma - Product Status 24

Optune - Mesothelioma - Product Description 24

Optune - Mesothelioma - A Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination with TTFields (150 kHz) as First-line Treatment in Malignant Pleural Mesothelioma 25

Optune - Non - Small Cell Lung Cancer - Product Status 26

Optune - Non - Small Cell Lung Cancer - Product Description 26

Optune - Ovarian Cancer - Product Status 27

Optune - Ovarian Cancer - Product Description 27

Optune - Ovarian Cancer - A Phase III Pivotal Study of Tumor Treating Fields Concomitant with Weekly Paclitaxel in the Treatment of Platinum-resistant Ovarian Cancer: INNOVATE-3 28

Optune - Ovarian Cancer - An Open Label Pilot Study of the NovoTTF-100L(O) System (NovoTTF Therapy) (200 kHz) Concomitant with Weekly Paclitaxel for Recurrent Ovarian Carcinoma 28

Optune - Pancreatic Cancer - Product Status 29

Optune - Pancreatic Cancer - Product Description 29

Optune - Pancreatic Cancer - A Phase II Study of TTFields (150 kHz) Concomitant with Gemcitabine and TTFields Concomitant with Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma 30

Optune - Pancreatic Cancer - PANOVA - 3: A Phase III Study of TTFields with Gemcitabine and Nab-paclitaxel for Front - Line Treatment of Locally Advanced Pancreatic Adenocarcinoma (LAPC) 30

Optune - Pediatric Glioma - Product Status 31

Optune - Pediatric Glioma - Product Description 31

Optune - Pediatric Glioma - A Phase I Trial of the Optune NovoTTF-200A System with and without Concomitant Temozolomide and Bevacizumab in Pediatric Patients with High-grade Glioma (HUMC 1612) 32

Optune - Pediatric Glioma - Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-grade Glioma and Ependymoma 32

Optune - Prostate Cancer - Product Status 33

Optune - Prostate Cancer - Product Description 33

Optune - Renal Adenocarcinoma - Product Status 34

Optune - Renal Adenocarcinoma - Product Description 34

Optune - Squamous Non-Small Cell Lung Cancer - Product Status 35

Optune - Squamous Non-Small Cell Lung Cancer - Product Description 35

Optune - Urinary Transitional Cell Carcinoma - Product Status 36

Optune - Urinary Transitional Cell Carcinoma - Product Description 36

Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Status 37

Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Description 37

Optune With Marizomib And Temozolomide - Glioblastoma - Product Status 38

Optune With Marizomib And Temozolomide - Glioblastoma - Product Description 38

NovoCure Ltd, Key Employees 40

NovoCure Ltd, Subsidiaries 41

Glossary 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Ergomed Plc

Oxford BioMedica Plc

Vernalis Plc

NovoCure Ltd, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies

select a license
Single User License
USD 750 INR 53498
Site License
USD 1500 INR 106995
Corporate User License
USD 2250 INR 160493

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com